NCT04632706 is a Phase 1 clinical trial of Ivermectin in Covid19, sponsored by MedinCell S.A.

Who is sponsoring NCT04632706?

NCT04632706 is sponsored by MedinCell S.A.

What drugs are being tested in NCT04632706?

Interventions in NCT04632706: Ivermectin, Placebo.

Is NCT04632706 still recruiting?

NCT04632706 is currently completed. Last updated 27 December 2021.

Are results published for NCT04632706?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2021-12-27 · How we verify

NCT04632706

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19

Completed Phase 1 Results posted Last updated 27 December 2021

What this trial tests

Phase 1 trial testing Ivermectin in Covid19 in 24 participants. Completed in 9 March 2021.

Timeline

22 September 2020

Primary endpoint
9 March 2021

9 March 2021

Quick facts

Lead sponsor	MedinCell S.A
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	sequential
Masking	double
Primary purpose	other
Enrollment	24
Start date	22 September 2020
Primary completion	9 March 2021
Estimated completion	9 March 2021
Sites	1 location across United Kingdom

Drugs / interventions tested

Ivermectin (ivermectin) — full drug profile →
Placebo

Conditions studied

Covid19 — all drugs for Covid19 →

Sponsor

MedinCell S.A

Who can join

Adults 18 to 45, male only, with Covid19. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Pharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax]) Primary · D1, D2 and D28

Maximum plasma concentration (Cmax)

Day 1 after loading dose of 200mcg/kg (oral) for all active treatment groups

Group	Value	95% CI
50mcg/kg (Oral)	57.2	± 28.9
75mcg/kg (Oral)	41.7	± 73.5
100mcg/kg (Oral)	46.5	± 53.6

Day 2 (first day on respective dose of active treatment)

Group	Value	95% CI
50mcg/kg (Oral)	22.3	± 32.5
75mcg/kg (Oral)	24.4	± 42.5
100mcg/kg (Oral)	33.2	± 62.6

Day 28 (last day of active treatment)

Group	Value	95% CI
50mcg/kg (Oral)	23.3	± 52.8
75mcg/kg (Oral)	31.9	± 27.6
100mcg/kg (Oral)	44.4	± 68.8

Pharmacokinetic Concentrations - (Time to Reach Cmax [Tmax]) Primary · D1, D2 and D28

Time to reach Cmax (Tmax)

Day 1 after loading dose of 200mcg/kg (oral) for all active treatment groups

Group	Value	95% CI
50mcg/kg (Oral)	2.53	± 36.8
75mcg/kg (Oral)	3.03	± 50.6
100mcg/kg (Oral)	4.8	± 47.2

Day 2 (first day on respective dose of active treatment)

Group	Value	95% CI
50mcg/kg (Oral)	3.82	± 36.7
75mcg/kg (Oral)	2.85	± 38.8
100mcg/kg (Oral)	3.23	± 34.5

Day 28 (last day of active treatment)

Group	Value	95% CI
50mcg/kg (Oral)	2.83	± 39.2
75mcg/kg (Oral)	3.03	± 50.7
100mcg/kg (Oral)	3.03	± 39.4

Pharmacokinetic Concentrations - (Area Under the Plasma Concentration-time Curve From Zero to 24 Hours [AUC0-24hr]) Primary · D1, D2 and D28

area under the plasma concentration-time curve from zero to 24 hours (AUC0-24hr) concentration-time curve from zero to 24 hours (AUC0-24hr)

Day 1 after loading dose of 200mcg/kg (oral) for all active treatment groups

Group	Value	95% CI
50mcg/kg (Oral)	568	± 33.6
75mcg/kg (Oral)	449	± 62.0
100mcg/kg (Oral)	523	± 60.5

Day 2 (first day on respective dose of active treatment)

Group	Value	95% CI
50mcg/kg (Oral)	906	± 31.4
75mcg/kg (Oral)	779	± 53.1
100mcg/kg (Oral)	941	± 59.0

Day 28 (last day of active treatment)

Group	Value	95% CI
50mcg/kg (Oral)	1.06	± 36.6
75mcg/kg (Oral)	1.5	± 47.5
100mcg/kg (Oral)	1.75	± 20.6

Pharmacokinetic Concentrations - (Apparent Terminal Half-Life [T1/2]) Primary · D28

apparent terminal half-life (t1/2)

Group	Value	95% CI
50mcg/kg (Oral)	102	± 60.1
75mcg/kg (Oral)	99.2	± 47.3
100mcg/kg (Oral)	127	± 47.2

Safety and Tolerability - Treatment Emergent Adverse Events (TEAEs) Secondary · From Screening (Day -28) to Follow up visit (Day +42) plus 7 additional days.

Clinical safety data from adverse event (AE) reporting

Any TEAE

Group	Value	95% CI
50mcg/kg (Oral)	24
75mcg/kg (Oral)	5
100mcg/kg (Oral)	2
Matching Placebo (Oral)	21

Any serious TEAE

Group	Value	95% CI
50mcg/kg (Oral)	0
75mcg/kg (Oral)	0
100mcg/kg (Oral)	0
Matching Placebo (Oral)	0

Any TEAE leading to discontinuation - due to Study Medication-related TEAE

Group	Value	95% CI
50mcg/kg (Oral)	0
75mcg/kg (Oral)	0
100mcg/kg (Oral)	0
Matching Placebo (Oral)	0

Any TEAE leading to discontinuation - other reason

Group	Value	95% CI
50mcg/kg (Oral)	0
75mcg/kg (Oral)	0
100mcg/kg (Oral)	1
Matching Placebo (Oral)	0

TEAE - mild severity

Group	Value	95% CI
50mcg/kg (Oral)	24
75mcg/kg (Oral)	5
100mcg/kg (Oral)	2
Matching Placebo (Oral)	20

TEAE - moderate severity

Group	Value	95% CI
50mcg/kg (Oral)	0
75mcg/kg (Oral)	0
100mcg/kg (Oral)	0
Matching Placebo (Oral)	1

Causality (All TEAEs) - Not related

Group	Value	95% CI
50mcg/kg (Oral)	21
75mcg/kg (Oral)	3
100mcg/kg (Oral)	2
Matching Placebo (Oral)	20

Causality (All TEAEs) - Related (possibly and probably)

Group	Value	95% CI
50mcg/kg (Oral)	3
75mcg/kg (Oral)	2
100mcg/kg (Oral)	0
Matching Placebo (Oral)	1

Adverse events — posted to ClinicalTrials.gov

Time frame: From Screening (Day -28) to Follow up visit (Day +42) plus 7 additional days. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

50mcg/kg (Oral)

Serious: 0/6 (0%)

Deaths: 0/6

75mcg/kg (Oral)

Serious: 0/6 (0%)

Deaths: 0/6

100mcg/kg (Oral)

Serious: 0/6 (0%)

Deaths: 0/6

Matching Placebo (Oral)

Serious: 0/6 (0%)

Deaths: 0/6

Ivermectin Overall

Serious: 0/18 (0%)

Deaths: 0/18

Total (Ivermectin Overall and Placebo)

Serious: 0/24 (0%)

Deaths: 0/24

Other adverse events (30 terms — click to expand)

Reaction	System	50mcg/kg (Oral)	75mcg/kg (Oral)	100mcg/kg (Oral)	Matching Placebo (Oral)	Ivermectin Overall	Total (Ivermectin Overall …
Headache	Nervous system disorders	—	—	—	—	—	—
Nausea	Gastrointestinal disorders	—	—	—	—	—	—
Dizziness	Nervous system disorders	—	—	—	—	—	—
Lethargy	Nervous system disorders	—	—	—	—	—	—
Rash	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Palpitations	Cardiac disorders	—	—	—	—	—	—
Somnolence	Nervous system disorders	—	—	—	—	—	—
Epistaxis	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Oropharyngeal pain	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—	—	—	—
Toothache	Gastrointestinal disorders	—	—	—	—	—	—
Chest discomfort	General disorders	—	—	—	—	—	—
Oral herpes	Infections and infestations	—	—	—	—	—	—
Back injury	Injury, poisoning and procedural complications	—	—	—	—	—	—
Burns first degree	Injury, poisoning and procedural complications	—	—	—	—	—	—
Exposure to communicable disease	Injury, poisoning and procedural complications	—	—	—	—	—	—
Joint injury	Injury, poisoning and procedural complications	—	—	—	—	—	—
Limb injury	Injury, poisoning and procedural complications	—	—	—	—	—	—
Transaminases increased	Investigations	—	—	—	—	—	—
Decreased appetite	Metabolism and nutrition disorders	—	—	—	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—	—	—	—
Muscle twitching	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Myalgia	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Neck pain	Musculoskeletal and connective tissue disorders	—	—	—	—	—	—
Paraesthesia	Nervous system disorders	—	—	—	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Nasal congestion	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Rhinorrhoea	Respiratory, thoracic and mediastinal disorders	—	—	—	—	—	—
Eczema	Skin and subcutaneous tissue disorders	—	—	—	—	—	—
Pruritus	Skin and subcutaneous tissue disorders	—	—	—	—	—	—

Data from ClinicalTrials.gov NCT04632706 adverse events section.

Sponsor's own description

An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19.
Scarabel L, Guardascione M, Dal Bo M, Toffoli G. · · 2021 · cited 12× · PMID 33476760 · DOI 10.1016/j.ijid.2021.01.035

Verify or expand the search:

Other trials of Ivermectin

Trials testing the same drug.

NCT07396714 — the Efficacy of Ivermectin Alone or With Microneedling in Treatment of Cutaneous Warts. · EARLY_PHASE1 · not yet recruiting
NCT07145736 — Moxidectin Versus Ivermectin as Mass Drug Administration for the Control of Onchocerciasis and Other Neglected Tropical · Phase 4 · recruiting
NCT05605925 — Ivermectin-artemisinin Combination Therapy for Eradication of Malaria · Phase 4 · unknown
NCT05045937 — Observational Study on the Use of Ivermectin as an Outpatient Treatment Option for COVID-19 · unknown
NCT05643820 — Comparison of Oral Ivermectin and Permethrin 5% Lotion in Treatment of Pediculosis Capitis · Phase 1 · completed

Other recruiting trials for Covid19

Currently open trials in the same condition.

NCT03305341 — Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix · EARLY_PHASE1 · active not recruiting
NCT06482138 — Dysfunction of Olfaction After COVID-19 Infection: Morphological and Histomolecular Investigation · NA · recruiting
NCT04924803 — Community Developed Technology-Based Messaging to Increase COVID-19 Vaccine Uptake Among People Who Inject Drugs · NA · active not recruiting
NCT05013632 — COVID-19 International Drug Pregnancy Registry · recruiting
NCT04806061 — Urine Alkalinisation in COVID-19 · NA · active not recruiting

Other MedinCell S.A trials

Trials by the same sponsor.

NCT05305560 — A Study to Evaluate the Efficacy and Safety of Ivermectin in COVID-19 Prevention · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04632706 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by MedinCell S.A
Last refreshed: 27 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04632706.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT04632706

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Sponsor's own description

Publications & conference data

Related trials

Other trials of Ivermectin

Other recruiting trials for Covid19

Other MedinCell S.A trials

Verify against primary sources